Get the Stockscreener App
114.14
1.08%
-1.36
After Hours:
114.14
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $114.14, with a volume of 3.60M.
It is down -1.08% in the last 24 hours and down -2.18% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$115.50
Open:
$115.31
24h Volume:
3.60M
Relative Volume:
0.79
Market Cap:
$199.50B
Revenue:
$41.22B
Net Income/Loss:
$5.77B
P/E Ratio:
38.82
EPS:
2.94
Net Cash Flow:
$6.49B
1W Performance:
-1.48%
1M Performance:
-2.18%
6M Performance:
+7.98%
1Y Performance:
+7.56%
1-Day Range:
$114.01
$115.58
1-Week Range:
$113.85
$116.39
52-Week Range:
$99.71
$121.64
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
114.14 | 199.50B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
376.16 | 144.82B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
90.55 | 133.46B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
82.93 | 106.63B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.80 | 43.59B | 6.60B | 4.16B | 490.10M | 6.93 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them - Benzinga
Teachers Retirement System of The State of Kentucky Purchases 97,343 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Toronto Dominion Bank Sells 220,223 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Groupama Asset Managment Acquires 41,557 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Baby Nutrition Market Size, Growth Status to 2033 Danone, Abbott - openPR
Lightning Round: Abbott Labs' legal trouble is largely behind it, says Jim Cramer - MSN
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
In-Vitro Toxicology Testing Market Projected to Reach USD 30.06 Bn by 2033 - GlobeNewswire Inc.
Abbott Laboratories (NYSE:ABT) Stock Position Lifted by Geode Capital Management LLC - MarketBeat
Vestcor Inc Trims Stake in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Expands Biowearables for Health and Wellness - The Healthcare Technology Report.
Why Is Abbott Laboratories (ABT) Among the Best Dividend Kings to Invest In For Safe Dividend Growth? - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Prostate Cancer Diagnostics Industry Business Report 2024 - GlobeNewswire Inc.
Diabetes Devices Market Next Big Thing | Major Giants- Abbott Laboratories, Bayer AG, Lifescan - openPR
Insiders At Abbott Laboratories Sold US$3.0m In Stock, Alluding To Potential Weakness - Yahoo Finance
Y Intercept Hong Kong Ltd Takes $5.49 Million Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Nomura Asset Management Co. Ltd. Purchases 68,779 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Medical Nutrition Market Top Companies StudyAbbott - openPR
First National Bank of Omaha Buys 5,683 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
MML Investors Services LLC Boosts Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott's Big Ten Blood Drive Campaign Saves 60,000 Lives, Awards $1M Health Grant - StockTitan
Abbott Labs Confirms Justice Department Probe Following Infant Formula Crisis - Main Street Media of Tennessee
Kovitz Investment Group Partners LLC Buys 76,876 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Purchased by Wellington Management Group LLP - MarketBeat
Abbott Laboratories stock rises Friday, still underperforms market - MarketWatch
Peering Into Abbott Laboratories's Recent Short Interest - Benzinga
Malaria Diagnostics Market Overview Report 2024 - GlobeNewswire Inc.
Worldquant Millennium Advisors LLC Reduces Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Two Sigma Advisers LP Cuts Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Stock Holdings Reduced by Quadrature Capital Ltd - MarketBeat
Prostate Health Market Overall Study Report 2024-2031 | Abbott - openPR
Abbott Laboratories (BUE:ABT) 10-Year Sharpe Ratio : 1.12 (As of Dec. 05, 2024) - GuruFocus.com
Abbott Accused Of 'Last-Ditch Effort' To Halt Formula Suit - Law360
Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
January 2025 Options Now Available For Abbott Laboratories (ABT) - Nasdaq
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Position Boosted by Stifel Financial Corp - MarketBeat
Quantinno Capital Management LP Buys 48,399 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up - Yahoo Finance
Royal London Asset Management Ltd. Purchases 19,763 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
ABT (Abbott Laboratories) 3-Year EBITDA Growth Rate : 6.80% (As of Sep. 2024) - GuruFocus.com
Abbott Laboratories (FRA:ABL) EV-to-Revenue : 5.25 (As of Dec. 05, 2024) - GuruFocus.com
Abbott Laboratories (FRA:ABL) Price-to-Operating-Cash-Flow : 24.26 (As of Dec. 05, 2024) - GuruFocus.com
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - MSN
IHT Wealth Management LLC Has $5.28 Million Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott's SWOT analysis: stock resilience amid litigation challenges - Investing.com
Abbott Laboratories (BSP:ABTT34) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
Is Abbott Laboratories Stock Underperforming the Nasdaq? - Nasdaq
Is Abbott Laboratories Stock Underperforming The Nasdaq? - Barchart
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT |
Oct 21 '24 |
Option Exercise |
47.00 |
157,421 |
7,398,787 |
342,227 |
| ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT |
Oct 21 '24 |
Sale |
117.04 |
157,421 |
18,424,298 |
184,806 |
1.75%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):